Chryso Pefkaros Katsoufis

Chryso Pefkaros Katsoufis

Auto-generated profile, based on publicly available information

Chryso Pefkaros Katsoufis

Division of Pediatric Nephrology Department of Pediatrics University of Miami Miller School of Medicine Miami Florida USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CKChryso Pefkaros Katsoufis
Chryso Pefkaros Katsoufis

14 March 2024 in Clinical Transplantation
Verified
Journal Article
Open access
WGWendy Glaberson
Wendy Glaberson
WSWacharee Seeherunvong
Wacharee Seeherunvong
JGJeffrey Gaynor
Jeffrey Gaynor
CKChryso Katsoufis
Chryso Katsoufis
MDMarissa J. Defreitas
Marissa J. Defreitas
JCJayanthi Chandar
Jayanthi Chandar
Introduction: Hyperparathyroidism (HPT) can contribute to metabolic bone disease following kidney transplantation. We evaluated post‐transplant trends in intact parathyroid hormone (iPTH) and determined predictors of HPT in pediatric kidney transplant (KTx) recipients.Methods: In this single‐center study, retrospective data were collected on 88 children from 2013 to 2019. Data collected included dialysis vintage, biochemical parameters, post‐transplant trends in iPTH, 25(OH)Vitamin D levels and estimated glomerular filtration rate (eGFR ml/min/1.73 m2). Pre‐transplant treatment for HPT was quantified with a Treatment Burden score (TB, score range: 0‐100). After log‐transforming skewed variables (iPTH and eGFR), multivariable linear regression was performed to determine predictors of log {iPTH} at 6 and 36 months (mo) post‐transplant.Results: Median age was 12.8 (range: 1.9‐20.5) years, and dialysis vintage was 11.2 (range: 0.0‐112.9) months. The majority were of Hispanic and African Ancestry (77.3%). Median post‐transplant iPTH was 69.5 (range: 1.8‐306.8) pg/ml at 6 mo with a gradual downward trend to 59.0 (range: 28.0‐445.0) pg/ml at 36 mo. Significant multivariable predictors of higher log {iPTH} post‐transplant included longer dialysis vintage, higher TB, and lower log{eGFR} at 6 mo, and higher TB, lower log{eGFR}, and deceased donor transplant at 36 mo.Conclusions: Recognition of risk factors for HPT and monitoring iPTH post‐transplant may facilitate timely interventions to mitigate cardiovascular and bone disease in pediatric KTx recipients.Key Message: Describe serial trends in intact PTH after kidney transplantation. Pre‐ and post‐transplant factors that contribute to persistence or re‐occurrence of hyperparathyroidism after kidney transplantation in children include longer dialysis vintage, high pre‐transplant treatment burden and decreased post‐transplant GFR. Recognition of these factors, and monitoring intact PTH after kidney transplantation, could facilitate timely interventions to mitigate cardiovascular and bone disease in children.

18 July 2025 in Prenatal Diagnosis
Verified
Journal Article
Open access
ABAdriana Baez
Adriana Baez
GTGabriele Tonni
Gabriele Tonni
CKChryso P. Katsoufis
Chryso P. Katsoufis
AAAmanda Alladin
Amanda Alladin
UPUgo Maria Pierucci
Ugo Maria Pierucci
RRRodrigo Ruano
Rodrigo Ruano
Serial amnioinfusion therapy (SAT) has emerged as a potential mitigatory intervention to adverse perinatal outcomes associated with congenital bilateral renal agenesis (BRA). However, its efficacy, safety, and ethical implications warrant thorough evaluation. This systematic review, developed according to PRISMA guidelines, analyzes the published data on outcomes of SAT for BRA and explores its implications. Inclusion criteria were a diagnosis of bilateral renal agenesis, therapeutic use of amnioinfusion, amnioinfusion procedure, and individual maternal and fetal outcome reports. A total of 192 published studies were identified. Among these, 11 full texts were included (N = 40). Only cases resulting in live birth and with reported maternal and neonatal outcomes were analyzed. The average number of amnioinfusions per mother was 9 (n = 23; range 1–26 infusions). Median gestational age at delivery was 33.4 weeks (n = 40; range 23.7–36.8 weeks). APGAR scores (n = 14) at 1 and 5 min were 4 and 6, respectively. Almost half of newborns died within 33 days of life (n = 19) and 7 (17.5%) survived at the time of original publication. Overall neonatal mortality was 82.5% (33 of 40). These findings suggest that SAT for BRA improves the chances of neonatal survival in the first few days to weeks of life but not consistently beyond that time. Additional advances in neonatal care are needed to improve long‐term outcomes in peripartum survivors.

14 October 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
CKChryso Pefkaros Katsoufis
Chryso Pefkaros Katsoufis
MDMarissa DeFreitas
Marissa DeFreitas
JLJessica Leuchter
Jessica Leuchter
WSWacharee Seeherunvong
Wacharee Seeherunvong
JCJayanthi Chandar
Jayanthi Chandar
CACarolyn Abitbol
Carolyn Abitbol
Background: Severe congenital lower urinary tract obstruction (cLUTO) is associated with poor postnatal outcomes, including chronic and end stage kidney disease, and high mortality. Studies of the impact of fetal intervention through vesicoamniotic shunting are marred by a device malfunction rate of up to 60%. In this study, we delineate the postnatal course and infant kidney function following definitive urinary diversion in utero.Materials and Methods: This is a retrospective, single-center cohort study of 16 male infants who survived the fetal intervention to birth, from 2010 to 2014 at a single center. All had patent shunts in place at birth. Perinatal and biochemical characteristics were collected with patients followed for one year, or until demise, with serial measures of serum creatinine (SCr) and serum cystatin C (CysC).Results: Of the 16 males, 81% were non-white (38% black, 43% Hispanic). Shunts were placed at a median of 20 weeks (IQR 19,23) gestation, with median fetal bladder volume of 39 cm3 (IQR 9.9,65). All neonates were born preterm [median 34 weeks (IQR 31,35)] and the majority with low birth weight [median 2340 grams (1,895, 2,600)]. 63% required positive pressure ventilation. Advanced chronic kidney disease stage 4–5 at 1 year of age was predicted by neonatal characteristics: peak SCr ≥2 mg/dl, time to peak SCr > 6 days, discharge SCr ≥1.0 mg/dl, CysC ≥2.5 mg/l, urine protein:creatinine ≥4.8 mg/mg, urine microalbumin:creatinine ≥2.2 mg/mg. In infancy, a nadir SCr ≥0.5 mg/dl occurring before 160 days (5.3 months) of age was also predictive of advanced chronic kidney disease stage 4–5 at 1 year. Three patients died in the neonatal period, with 1 receiving kidney replacement therapy (KRT). Three additional patients required KRT before 12 months of age.Conclusions: Even with definitive vesicoamniotic shunting for cLUTO, postnatal morbidity and mortality remain high, emphasizing the role of renal dysplasia, in spite of urinary diversion, in postnatal kidney dysfunction. Neonatal and infant biochemical parameters exhibit distinct trends that offer families and physicians a better understanding of the prognosis of childhood kidney function.